We are honored to partner with GAVI, which is launching the African Vaccine Manufacturing Accelerator to increase vaccine production across Africa. DFC is committed to working with our G7 and private sector partners to ensure the world is prepared for future health crises.
Congratulations, Nafisa Jiwani and Nisha Biswal and team!
🌍💉 The inequitable rollout of COVID-19 vaccines drew global attention to the lack of vaccine manufacturing capacity in Africa. Significant political and financial investment have since been made on the continent, creating growth momentum behind the industry. CII and the Bill & Melinda Gates Foundation worked with Clinton Health Access Initiative, Inc. to publish "Continental Market-shaping Strategy for a Sustainable Vaccine Manufacturing Footprint in Africa". This white paper offers a view on targeting a compromise between the three major objectives global health stakeholders have towards African vaccine manufacturing expansion. Check out the white paper and complementing briefing examining current and planned vaccine manufacturing capacity in Africa at the links in the comments→
🔥 What are the major risks to markets that can sustainably support vaccine manufacturing in Africa and what can be done to mitigate them? Check out the latest analysis and a continental market shaping strategy put forth by the Clinton Health Access Initiative, Inc., led by Frauke Uekermann and her team with support from CII's very own Dipa Sharif-Ahmed. White paper link in the comments -->
🌍💉 The inequitable rollout of COVID-19 vaccines drew global attention to the lack of vaccine manufacturing capacity in Africa. Significant political and financial investment have since been made on the continent, creating growth momentum behind the industry. CII and the Bill & Melinda Gates Foundation worked with Clinton Health Access Initiative, Inc. to publish "Continental Market-shaping Strategy for a Sustainable Vaccine Manufacturing Footprint in Africa". This white paper offers a view on targeting a compromise between the three major objectives global health stakeholders have towards African vaccine manufacturing expansion. Check out the white paper and complementing briefing examining current and planned vaccine manufacturing capacity in Africa at the links in the comments→
"At the time when the documents were released and the letter written to the World Health Organization, it was difficult for us. I´ve been in discussions and in conversations in the media, because I could not understand why a small insignificant African biotech start-up company, that is so committed to access and to contributing by building the vaccine sector in Africa would be a threat. I would have thought we would have been a potential partner. How is it possible that we could attract attention at such a global level? But in fact, it motivated us." Professor Petro Terblanche, Managing Director of Afrigen Biologics (Pty) Ltd talking to Lenias Hwenda on Let´s Talk about Health in Africa on Utano Podcast. Prof. Terblanche talks about how the difficulties her company struggled with from the attacks from kENUP Foundation which acts on behalf of BioNTech SE. In a wide ranging conversation, she discusses a range of issues including 📌the progress Afrigen has made against all odds 📌what´s coming in Afrigen´s pipeline and 📌why she is hopeful about the future. Click the link below to watch the trailer👉🏾https://lnkd.in/eKPSFx6k 📣Tune in for the full conversation coming 1 January 2024. #africa #health #healthcare #medicines #vaccines #publichealth #biontech #kENUP #afrigen #mrnavaccines
African Export-Import Bank (Afreximbank) and the Africa Centers for Diseases Control and Prevention (Africa CDC have renewed their partnership with a new cooperation agreement announced today on the sidelines of the Global Forum for Vaccine Sovereignty and Innovation in Paris, France. Through this collaboration, Afreximbank has committed a US$ 2 billion facility to the “Africa Health Security Investment Plan” to support the health product manufacturing ambition of the continent. This initiative will focus on the African Pooled Procurement Mechanism (APPM) and the Platform for Harmonized African Health Products Manufacturing (PHAHM). This initiative is pivotal in addressing Africa's health investment challenges, promoting economic development, and strengthening health security across the continent. It also intends to complement GAVI's innovative financing mechanism, the African Vaccine Manufacturing Accelerator (AVMA) which is set to provide up to USD 2 billion financing to African manufacturers of health and pharmaceutical products over the next ten years.
Member states of the WHO have resumed negotiations to finalize a pandemic agreement based on lessons from COVID-19. The agreement aims to strengthen global measures to prevent infectious diseases and spread of new viruses and is expected to be adopted at the WHO's general assembly in May. The draft agreement includes provisions for national pandemic prevention plans, financial assistance for developing countries, technology transfer for vaccine and drug production, and reduced royalties for pandemic-related health products. Developing countries are pushing for patent holders to forgo royalties, while developed nations are concerned about the impact on pharmaceutical firms. Uncertainty remains on whether an agreement will be reached before the final meeting in May. #AsiaRisk #EpidemicsandPandemics #Japan Follow us for daily updates on risk and operations in Asia! https://lnkd.in/gX-c3-YJ
In the News: New $1 billion plan for African vaccine manufacturing 🌟 Discover the latest in the world of FDI and Business! Check out this insightful piece. 💡🌍 Up to $1 billion will be available to boost African vaccine manufacturing as part of a new scheme set up by Gavi, the Vaccine Alliance, the global health organisation said on Thursday. 🔗 [Learn more: https://lnkd.in/gJycJJkE] 🗨️ Join the Discussion! Your opinions are invaluable. #Comment below to share your views, ask questions, or start a conversation. We're excited to engage with each comment and hear what you think! Join as a Partner and Professional: FDI Alliance: www.fdialliance.com Valqus Accounting and Business: www.valqus.com #FDI #Invest #Trade #TradeandInvest #InvestmentPromotion #Markets #Business #Accounting
Technical Officer at Impact Global Health | Advancing Healthcare Access in Africa through Data-Driven Solutions | Health Research and Policy | Global Health and Development |
🌟 Status of Diagnostics, Therapeutics and Vaccines for #Mpox on Day Zero: According to the 2023 #GFINDER survey (Policy Cures Research https://lnkd.in/dsM8P5FD), in its first year of recorded funding (in 2022), 📋 💊 💉 #Mpox R&D received: – $66 million for diagnostics, therapeutics and vaccines; – $1.2 million for diagnostics; – $36 million for therapeutics (including $82,000 biologics); – $28 million for vaccines –(N.B there were already two approved vaccines). 🌟 By comparison, #COVID19 received a total of $3.7bn across all three tools: -$2.4bn for vaccines, -$1.1 bn for therapeutics (including $222m for biologics) -$195m for diagnostics in 2022. 🌟 Despite this funding, and despite the wake up call of the 2022 PHEIC, at present, #Mpox drugs, therapeutics and vaccines access and availability is limited. Drugs, therapeutics and vaccines, in addition to non-pharmaceutical interventions, will be crucial for a swift response. Policy Cures Research International Pandemic Preparedness Secretariat
The clock starts now for the #100DaysMission for #mpox. What diagnostics, therapeutics and vaccines are available on Day Zero? What are the priority actions for the next 100 days? ➡ Read the IPPS statement by Mona Nemer, Victor Dzau, and Shingai Machingaidze in response to #mpox being declared as a #PHEIC and #PHECS: https://lnkd.in/eTCtQEbR At IPPS, we are committed to working with #100DaysMission implementing partners to bring an end to the Mpox outbreak. IPPS encourage the international community to provide Africa CDC, World Health Organization and affected governments with the necessary support and funding to respond effectively, whilst strengthening pandemic preparedness at national, regional and global levels. CEPI (Coalition for Epidemic Preparedness Innovations) FIND Unitaid IFPMA INTREPID Alliance Wellcome Trust Bill & Melinda Gates Foundation PATH IQVIA Global Access Dx (GADx) Policy Cures Research
Check out this joint statement from the WHO-UNICEF encouraging greater health commodity supply chain integration for temperature-sensitive pharmaceuticals where appropriate. This statement highlights integration as a practical solution and references planning tools and other existing mechanisms to design and implement a safe and efficient integrated cold chain system. The following recommendations are provided: 1. Safety considerations 2. Cold chain capacity assessment and forecasting 3. Integration and documentation 4. Communication and coordination 👉Full statement here: https://ow.ly/GsKG50RchmR World Health Organization UNICEF Gavi, the Vaccine Alliance JSI VillageReach USAID PATH Bill & Melinda Gates Foundation The Global Fund Clinton Health Access Initiative, Inc.
Join us in raising awareness about tuberculosis (TB) on World Tuberculosis Day! In our latest video presentation, the Pharmaceutical Association of Nigerian Students Public Health Committee at Kaduna State University sheds light on this global health issue and what we can do to make a difference. #WorldTBDay2024
The #availability of #essentialmedicines with guaranteed #quality plays a crucial role in the #advancement of global health #goals, such as eliminating #preventable deaths of new-borns and children under five, combating waterborne and other #communicablediseases, ending the #epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases, and achieving universal health coverage (#UHC). There are frequently gaps or #shortages in the #globalsupply of certain essential medicines because there are #few or no #GMP-compliant manufacturers producing it. Encouraging pharmaceutical producers to meet #global quality #standards, like World Health Organization prequalification (#WHOPQ), can assist in resolving concerns about the availability of quality-assured essential medicines. Through The World Bank-funded #IMPACT project, Bloom Public Health, in #partnership with #NIPRD, worked to #strengthen the capacities and capabilities of local pharmaceutical manufacturers in #Nigeria to produce quality-assured medicines and address critical shortages or gaps in the supply of essential medicines. In the past ten months, Bloom Public Health, in this landmark pharmaceutical intervention, has been providing #technicalassistance to #five selected local #pharmaceuticalmanufacturers in #Nigeria towards the attainment of #WHOPQ of their #antimalarials and further bioavailability/bioequivalence studies support for one of the pharmaceutical manufacturers. This #intervention is sure to address issues of #medicinesecurity, and poor-quality essential medicines, while providing local pharmaceutical manufacturers with vast #opportunities to #access the global medicine market, making them #eligible for donor-sponsored tenders for medicines. Bloom Public Health is taking significant #steps towards #transforming the pharmaceutical manufacturing sector in #Nigeria through diverse interventions, and we will not rest on our oars until we achieve our #goal. 📹:Snippets of the #IMPACT project's capacity-building workshop #TheWorldBank #IMPACTproject #pharmaceuticalmanufacturers #WHOPQ #capacitybuilding #GMP #Standards #qualitymedicines #antimalarials #NIPRD #BloomPublicHealth #Nigeria #Cameroon #Rwanda #Botswana #Zambia
Dean of the Kogod School of Business at American University. Former Executive at The Carlyle Group. Author.
3mo👏🏻👏🏻👏🏻 Nafisa Jiwani